Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Drug: Nab-paclitaxel combined with S-1
- Registration Number
- NCT03977220
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Brief Summary
Investigators assessed the effectiveness of Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
- Detailed Description
Adjuvant chemotherapy is still the standard of care for stage Ⅲ gastric cancer. Till now, oxaliplatin with capecitabine or S1 still the standard chemotherapy regimen. Howerver, the prognosis of diffuse type gastric cancer patients is still poor even after adjuvant chemotherapy of XELOX or S1 regimen. Several retrospective, single institutional studies have shown that the addition of Nab-paclitaxel to S1 can prolong the survival of advanced gastric cancer with diffuse type.However, the effection of Nab-paclitaxel and S1 is unknown in diffuse gastric cancer patients after radical surgery. We assessed the effectiveness of radical surgery following docetaxel, nab-pacitaxel and S1 therapy for gastric cancer with diffuse type.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
- gastric cancer patients after radical resection
- diffuse type gastric cancer stage III
- Patients who have metastasis disease
- Patients who can not tolerate chemotherapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Nab-paclitaxel combined with S-1 Nab-paclitaxel combined with S-1 Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
- Primary Outcome Measures
Name Time Method Recommended dose for Phase II study through study completion, an average of 2 year
- Secondary Outcome Measures
Name Time Method